Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

"Vascular access complications represent a significant healthcare problem, and we were impressed by the market opportunity for PRT-201 and with the quality of Proteon's team," said Dr. Steven St. Peter, Managing Director of MPM Capital. "We are pleased to be a part of this successful financing structure, and I look forward to working closely with Proteon."

About PRT-201

PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit www.proteontherapeutics.com.

About MPM Capital

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2.4 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held companies ... three years through 2014. Being named to the Inc. 5000 list designates a company ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated Tad ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a ... US laboratory is to open in Manhattan, Kansas in early October, 2015. The ... growth of research and development through collaboration with researchers from Kansas State University’s ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... While the University of Wisconsin-Madison continues to make ... cultures announced over the weekend, things aren't going so ... , ,Hwang Woo-suk, a South Korean stem-cell researcher, ... accusations surfaced that he fabricated stem-cell research results. , ...
... and hello, 2006! I sit hear writing this article as ... "Cream Gold" (released in 2005 - not to be confused ... you may ask? Well, the successful re-emergence of this supergroup ... and NewYork's Madison Square Gardens marked a 2005 musical highlight ...
... recently, you have probably heard about the collapse of ... after being accused of allegedly hiding a $430 million ... has been arrested, and while his innocence or guilt ... excellent opportunity to understand the serious interdependencies between IT ...
Cached Biology Technology:Stem-cell controversies slow progress 2Biotech flourishes in 2005 while Big Pharma is on the decline 2Biotech flourishes in 2005 while Big Pharma is on the decline 3Biotech flourishes in 2005 while Big Pharma is on the decline 4Biotech flourishes in 2005 while Big Pharma is on the decline 5Biotech flourishes in 2005 while Big Pharma is on the decline 6Biotech flourishes in 2005 while Big Pharma is on the decline 7Biotech flourishes in 2005 while Big Pharma is on the decline 8The role of IT in Sarbanes-Oxley Section 404 2The role of IT in Sarbanes-Oxley Section 404 3
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... 600 million years ago, before the rapid evolution of ... of seaweeds and worm-like animals lived in a quiet ... village in south China. Then they simply died, ... of black shale deposited in oxygen-free and unbreathable waters. ...
... awarded a prestigious Sloan Research Fellowship. Chen, a Canada ... subject: deciphering the assembly instructions for the brain. ... with precision. One of the central puzzles in neuroscience ... during its development when faced with thousands of potential ...
... The following studies will be presented in the Press Program ... multipartner initiative for physicians of all medical disciplines dealing with ... of the embargoed press releases/abstracts can be requested to the ... lifts, the texts will be available in the ESMO Online ...
Cached Biology News:Oldest fossils of large seaweeds, worm-like animals tell story of ancient oxygen 2Oldest fossils of large seaweeds, worm-like animals tell story of ancient oxygen 3Prestigious Sloan Fellowship awarded 2European Multidisciplinary Conference in Thoracic Oncology -- press program 2
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: